English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Osteoporosis is a common systemic skeletal disorder resulting in bone fragility and increased fracture risk. It is still necessary to explore its detailed mechanisms and identify novel targets for the treatment of osteoporosis. Previously, we found that a lncRNA named  GAS5  in human could negatively regulate the lipoblast/adipocyte differentiation. However, it is still unclear whether  GAS5  affects osteoblast differentiation and whether  GAS5  is associated with osteoporosis. Our current research found that  GAS5  was decreased in the bones and BMSCs, a major origin of osteoblast, of osteoporosis patients. Mechanistically,  GAS5  promotes the osteoblast differentiation by interacting with UPF1 to degrade  SMAD7  mRNA. Moreover, a decreased bone mass and impaired bone repair ability were observed in  Gas5  heterozygous mice, manifesting in osteoporosis. The systemic supplement of  Gas5 -overexpressing adenoviruses significantly ameliorated bone loss in an osteoporosis mouse model. In conclusion,  GAS5  promotes osteoblast differentiation by targeting the UPF1/SMAD7 axis and protects against osteoporosis.

GAS5 protects against osteoporosis by targeting UPF1/SMAD7 axis in osteoblast differentiation